These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 14731055)

  • 41. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget?
    Mauskopf J; Chirila C; Birt J; Boye KS; Bowman L
    Health Policy; 2013 Apr; 110(1):49-59. PubMed ID: 23434292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paucity and Inconsistency: A Systematic Review and Critique of Budget Impact Analyses of Disease-Modifying Therapies for Multiple Sclerosis in the UK and the Implications for Policy in the UK.
    Montgomery S; Kusel J; Allen F; Adlard N
    Appl Health Econ Health Policy; 2016 Oct; 14(5):545-58. PubMed ID: 27130689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Rutten FF; Brouwer WB
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health technology adoption and the politics of governance in the UK.
    Milewa T
    Soc Sci Med; 2006 Dec; 63(12):3102-12. PubMed ID: 16982120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality, bias and service user experience in healthcare: 10 years of mental health guidelines at the UK National Collaborating Centre for Mental Health.
    Kendall T; Glover N; Taylor C; Pilling S
    Int Rev Psychiatry; 2011 Aug; 23(4):342-51. PubMed ID: 22026490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors affecting the uptake of new medicines in secondary care - a literature review.
    Chauhan D; Mason A
    J Clin Pharm Ther; 2008 Aug; 33(4):339-48. PubMed ID: 18613851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exploring uncertainty in cost-effectiveness analysis.
    Claxton K
    Pharmacoeconomics; 2008; 26(9):781-98. PubMed ID: 18767898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Parr AT; Hirsch JA
    Pain Physician; 2011; 14(3):E249-82. PubMed ID: 21587337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A NICE fallacy.
    Quigley M
    J Med Ethics; 2007 Aug; 33(8):465-6. PubMed ID: 17664304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
    Devlin N; Parkin D
    Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of national agencies in the managed introduction of new drugs for arthritis.
    Simister K
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i38-40. PubMed ID: 11053085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Searching for cost effectiveness thresholds in the NHS.
    Appleby J; Devlin N; Parkin D; Buxton M; Chalkidou K
    Health Policy; 2009 Aug; 91(3):239-45. PubMed ID: 19168255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
    Barham L
    Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence-informed evidence-making.
    Chalkidou K; Walley T; Culyer A; Littlejohns P; Hoy A
    J Health Serv Res Policy; 2008 Jul; 13(3):167-73. PubMed ID: 18573766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.